METHODS: Post-hoc analysis of patients receiving tMCS for PCCS in the Sustain CSX trial, which investigated the effects of high-dose selenium on postoperative organ dysfunction in cardiac surgery patients.
PRIMARY OUTCOME: duration of tMCS therapy.
SECONDARY OUTCOMES: postoperative organ dysfunction and 30-day mortality.
RESULTS: Thirty-nine patients were treated with tMCS for PCCS. There was no difference in the median duration of tMCS between the selenium and the placebo group (3 days [IQR: 1-6] vs. 2 days [IQR: 1-7], p = 0.52). Median dialysis duration was longer in the selenium group (1.5 days [0-21.8] vs. 0 days [0-1.8], p = 0.048). There was no difference in 30-day mortality (53% vs. 41%, OR 1.44, 95% CI 0.32-6.47, p = 0.62).
CONCLUSION: In this explorative study, a perioperative high-dose selenium-supplementation did not show beneficial effects on organ dysfunctions and mortality rates in patients with PCCS receiving tMCS.
METHODS: In this secondary analysis of a multicenter study in Asia, peak serum PCT (measured within 5 days) was categorized into four groups (<0.5, 0.5-2.0, 2.0-10.0, and >10.0 ng/mL). The primary outcome was mortality and secondary outcomes were acute respiratory distress syndrome (ARDS), septic shock, and multiorgan dysfunction. Area under the receiver operating curve (AUROC) analysis was used to assess the association of peak PCT levels with primary and secondary outcomes.
RESULTS: Of 846 patients, 344 had early PCT data. Mortality increased in groups with higher peak PCT levels [8/162 (4.9%), 3/69 (4.4%), 8/55 (14.6%) vs. 11/58 (19.0%); P = 0.002]. The proportion of patients with ARDS [23/162 (14.2%), 14/69 (20.3%), 10/55 (18.2%) vs. 25/58 (43.1%); P